S8822

SB-525334

≥98% (HPLC), solid, ALK5 inhibitor

• Synonyme(s) : 6-[2-tert-butyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-quinoxaline
• Formule empirique (notation de Hill) : C₂₁H₂₁N₅
• CAS Number: 356559-20-1
• Poids moléculaire : 343.42
• Numéro MDL: MFCD11045307
• Code UNSPSC : 12352200
• ID de substance PubChem : 329824610
• Nomenclature NACRES : NA.77

Propriétés

• Product Name: SB-525334, ≥98% (HPLC)
• Niveau de qualité: 100
• Essai: ≥98% (HPLC)
• Forme: solid
• Couleur: yellow
• Solubilité: DMSO: ≥20 mg/mL
• Auteur: GlaxoSmithKline
• Température de stockage: 2-8°C
• Chaîne SMILES: Cc1cccc(n1)-c2[nH]c(nc2-c3ccc4nccnc4c3)C(C)(C)C
• InChI: 1S/C21H21N5/c1-13-6-5-7-16(24-13)19-18(25-20(26-19)21(2,3)4)14-8-9-15-17(12-14)23-11-10-22-15/h5-12H,1-4H3,(H,25,26)
• Clé InChI: DKPQHFZUICCZHF-UHFFFAOYSA-N

Description

Application

SB-525334 was used to study TGFβ1-mediated human trophoblast differentiation.⁷

Actions biochimiques/physiologiques

SB-525334 blocks the activation of Smad2/3 induced by TGFβ1 in renal proximal tubule cells.⁴ The sensitivity of TGFβ1 is decreased by SB-525334 that benefits the pulmonary arterial hypertension condition by reversing the pulmonary arterial pressure.⁵ SB-525334 is reduces the tumor incidence and size of mesenchymal tumors such as uterine leiomyoma.⁶

SB-525334 is a potent activin receptor-like kinase (ALK5)/ type I TGFβ-receptor kinase inhibitor with IC₅₀ = 14.3 nM.

SB-525334 is an ALK5/type I TGFβ-R kinase inhibitor.

Caractéristiques et avantages

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Informations sur la sécurité

• Code de la classe de stockage: 11 - Combustible Solids
• Classe de danger pour l'eau (WGK): WGK 3
• Équipement de protection individuelle: dust mask type N95 (US), Eyeshields, Faceshields, Gloves